BioCon Limited Collaborates With Advaxis, Inc. For "ADXS-HPV" A Novel Cancer Immunotherapy
Published: Jan 22, 2014
BANGALORE, India & PRINCETON, N.J.--(BUSINESS WIRE)--Biocon Ltd., (BIOCON.BO), Asia’s premier biotechnology company, and Advaxis, Inc., (NASDAQ: ADXS), a leader in developing the next generation of cancer immunotherapies, announced today that they have entered into an exclusive licensing agreement for co-development and commercialization of ADXS-HPV, a novel cancer immunotherapy for the treatment of human papillomavirus (HPV)-associated cervical cancer in women, for India and key emerging markets.
Help employers find you! Check out all the jobs and post your resume.